

104W



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Nancy Malsich
Nancy Malsich

1/19/07
Date

Applicant: Liang) Group: Unassigned
)
Serial No.: 10/580,670) Confirmation No.: Unassigned
)
Filed: May 26, 2006) Examiner: Unassigned
)
For: ADVANCED INDOLINONE BASED) Our Ref.: TSRI 1071.3 US
PROTEIN KINASE INHIBITORS)
)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability

unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

The Director is hereby authorized to charge our Deposit Account No. 19-0962 in the event that there are any charges associated with the present application.


Respectfully submitted,

1/19/07
Date

Donald G. Lewis
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 1071.3	SERIAL NO. 10/580,670
	APPLICANT Liang, et al.	
	FILING DATE 5/ 26/ 2006	GROUP Not assigned



U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	1	6,653,308 B2	Nov. 25, 2003	Guan, et al.			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)		
	2	McMahon, et al., "Protein Kinase Inhibitors: Structural Determinants for Target Specificity", <u>Curr. Opin. Drug Disc. Dev.</u> 1: 131-146 (1998)
	3	Sun, et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases", <u>J. Med. Chem.</u> 41: 2588-2603 (1998)
	4	Sun, et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases", <u>J. Med. Chem.</u> 42: 5120-5130 (1999)
	5	Laird, et al., "SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors", <u>Cancer Res.</u> 60: 4152-4160 (2000)
	6	Smolich, et al., "The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts", <u>Blood</u> 97: 1413-1421 (2001)
	7	Laird, et al., "SU6668 inhibits Flk-1/KDR and PDGFR β in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice", <u>FASEB J.</u> 16: 681-690 (2002)
	8	Mendel, et al., "In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship", <u>Clin. Cancer Res.</u> 9: 327-337 (2003)
	9	Sun, et al., "Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase", <u>J. Med. Chem.</u> 46: 1116-1119 (2003)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.